
HDAC2-IN-1

MedChemExpress

Cat. No.:	HY-151248	
CAS No.:	2919691-32-8	
Molecular Formula:	C ₂₂ H ₂₃ ClN ₄ OS	
Molecular Weight:	426.96	
Target:	HDAC	CI
Pathway:	Cell Cycle/DNA Damage; Epigenetics	\rightarrow
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	



BIOLOGICAL ACTIVITY						
Description	HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive HDAC2 inhibitor with an IC ₅₀ of 0.5 μ M ^[1] . HDAC2-IN-1 also inhibits HDAC1 and HDAC8 with IC ₅₀ s of 1.61 μ M and 0.98 μ M, respectively ^[1] .					
IC₅₀ & Target	HDAC2 0.5 μΜ (IC ₅₀)	HDAC8 0.98 μΜ (IC ₅₀)	HDAC1 1.61 μΜ (IC ₅₀)			
In Vitro	HDAC2-IN-1 (Compound 17) (3 and 10 μM; 48 h) increases histone H4K12 and H3K9 acetylation levels in SKNSH cells in a dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.					
In Vivo	HDAC2-IN-1 (Compound 17) (30 or 100 mg/kg; p.o.; once) shows good plasma and brain exposure, and shows promisi brain penetration ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.					
	Animal Model:	Male C57BL/6 mice ^[1]				
	Dosage:	30 or 100 mg/kg				
	Administration:	Oral administration (Pharmacokinetic Analysis)				

Showed good plasma and brain exposure, also showed promising brain penetration, $K_{\text{p},\text{uu}}$

= 0.36. Significantly increased histone H4K12 acetylation in mouse brain 4 h after oral

REFERENCES

Result:

[1]. Tamanini E, et al. Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor. ACS Medicinal Chemistry Letters, 2022.

dosing at 100 mg/kg.

Product Data Sheet

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA